July 17 The U.S. Food and Drug Administration
has called an advisory committee meeting on Sept. 17, to discuss
the adverse cardiovascular outcomes with the usage of
testosterone replacement therapy.
The FDA has called for a joint meeting of the bone,
reproductive and urologic drugs advisory committee and the drug
safety and risk management advisory committee. (1.usa.gov/1nPA7Qf)
In June, the FDA said that all testosterone products on the
market should include in their labels a general warning about
the risk of blood clots in veins.
These treatments are used by men who have low levels of
Products on the market or about to be launched include
AbbVie Inc's AndroGel, Endo International Plc's
Aveed and Trimel Pharmaceuticals Corp's
(Reporting By Amrutha Penumudi in Bangalore; Editing by Savio